[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100648648":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":29,"centralContacts":33,"locations":40,"responsibleParty":66,"collaborators":11,"id":69,"slug":70,"hasResults":71,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":11,"eligibilityCriteria":75,"healthyVolunteers":71,"sex":76,"minAge":77,"maxAge":11,"enrollmentInfo":78,"targetDuration":11,"studyType":81,"phases":82,"briefSummary":84,"conditions":85,"keywords":11,"overallStatus":87,"whyStopped":11,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":97},{"fullName":5,"class":6},"Chinese University of Hong Kong","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Conventional Transurethral Resection of Bladder Tumour (cTURBT)","ACTIVE_COMPARATOR",null,[13],"Procedure: Conventional Transurethral Resection of Bladder Tumour",{"label":15,"type":16,"description":11,"interventionNames":17},"Transurethral En Bloc Resection of Bladder Tumour (ERBT)","EXPERIMENTAL",[18],"Procedure: Transurethral En Bloc Resection of Bladder Tumour",[20,25],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":11},"PROCEDURE","Conventional Transurethral Resection of Bladder Tumour","Conventional TURBT is performed by resecting the bladder tumour in a piecemeal manner with a top-down approach. The bladder tumour specimen is fragmented during the procedure and whether a complete resection has been achieved is determined by the operating surgeon's judgment intra-operatively.",[9],{"type":21,"name":26,"description":27,"armGroupLabels":28,"otherNames":11},"Transurethral En Bloc Resection of Bladder Tumour","This surgical technique resects the bladder tumour underneath the submucosal plane, and the bladder tumour can be removed in one piece.",[15],[30],{"name":31,"affiliation":5,"role":32},"Yuen Chun Jeremy TEOH, MD","PRINCIPAL_INVESTIGATOR",[34,38],{"name":31,"role":35,"phone":36,"phoneExt":11,"email":37},"CONTACT","35053933","jeremyteoh@surgery.cuhk.edu.hk",{"name":39,"role":35,"phone":11,"phoneExt":11,"email":11},"Yuen Chun Jeremy TEOH",[41,55],{"facility":42,"status":11,"city":43,"state":11,"zip":11,"country":43,"countryCode":44,"cosmosGeoPoint":45,"geoPoint":50,"contacts":51},"Prince of Wales Hospital","Hong Kong","HK",{"type":46,"coordinates":47},"Point",[48,49],114.17469,22.27832,{"lat":49,"lon":48},[52],{"name":53,"role":35,"phone":54,"phoneExt":11,"email":37},"Jeremy Yuen-Chun TEOH, MBBS, FRCS(Ed), MD","35052625",{"facility":56,"status":11,"city":57,"state":11,"zip":11,"country":43,"countryCode":44,"cosmosGeoPoint":58,"geoPoint":62,"contacts":63},"North District Hospital","Sheung Shui",{"type":46,"coordinates":59},[60,61],114.11667,22.51667,{"lat":61,"lon":60},[64],{"name":65,"role":35,"phone":11,"phoneExt":11,"email":37},"Jeremy Yuen Chun TEOH, MBBS, FRCSEd, MD",{"type":32,"investigatorFullName":67,"investigatorTitle":68,"investigatorAffiliation":5,"oldNameTitle":11,"oldOrganization":11},"Jeremy Yuen Chun TEOH","Associate Professor","100648648","role-of-erbt-plus-intravesical-bcg-in-intermediate-risk-or-high-risk-nmbc-100648648",false,"NCT07724886","Role of ERBT Plus Intravesical BCG in Intermediate-Risk or High-Risk NMBC","A Randomised Trial Investigating the Role of Transurethral En Bloc Resection of Bladder Tumour Plus Intravesical Bacillus Calmette-Guerin Therapy, in Patients With Intermediate-Risk or High-Risk Non-Muscle-Invasive Bladder Cancer","Inclusion Criteria:\n\n* Age 18 years or above\n* Fulfil any one of the following three criteria:\n\n  1. Recurrent bladder tumour\n  2. Multiple bladder tumours\n  3. Any bladder tumour size of \\>1cm\n\nExclusion Criteria:\n\n* EAU low-risk NIMBC as intravesical BCG therapy should not be offered (5)\n* EAU very high-risk NMIBC as upfront radical cystectomy should be offered (5)\n* Any prior use of intravesical BCG therapy\n* Presence or prior history of upper urinary tract malignancy\n* Presence of clinically significant cardiovascular disease (History of acute myocardial infarction, presence of uncontrolled angina within 3 months before screening, New York Heart Association Class III or IV congestive heart failure, presence of ventricular arrhythmias, or presence of second-degree or third-degree heart block) (16)\n* Presence of GOLD Stage III or IV chronic obstructive pulmonary disease\n* ECOG performance status ≥ 2 (Ambulatory and capable of all self-care but unable to carry our any work activities) (18)\n* History of bleeding disorder or use of anti-coagulants\n* Pregnancy\n* Presence of other active malignancy","ALL","18 Years",{"count":79,"type":80},732,"ESTIMATED","INTERVENTIONAL",[83],"NA","This is a prospective, multi-centre randomised trial comparing between cTURBT plus 1-year BCG therapy, and ERBT plus 1-year BCG therapy, in patients with intermediate-risk or high-risk NMIBC.",[86],"Bladder Cancer","NOT_YET_RECRUITING","2026-07-31",{"date":90,"type":91},"2026-08-03","ACTUAL",{"date":93,"type":80},"2026-07-01",{"date":95,"type":80},"2030-03-31",{"name":5,"class":6},2]